Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

NCT03478462 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Pediatric Solid Tumor
Pediatric Lymphoma
Pediatric Brain Tumor
DIPG
Neuroblastoma
Ewing Sarcoma
Rhabdomyosarcoma
Osteosarcoma

Interventions

DRUG: CLR 131

Sponsor

Cellectar Biosciences, Inc.